Delivery Order SPE2DB22D1200-SPE2DB25FN3YM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,022.80 to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 Unit/ML insulin in 3ml quantities. This firm fixed price, competitively awarded contract was issued on July 22, 2025, with an ultimate completion date of July 23, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a single transaction executed...
- The Defense Logistics Agency awarded a $1,968.89 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Lantus SoloStar 100 Unit/ML insulin in 3 mL quantities. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of August 5, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,807.03 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 unit/mL 3 mL insulin, with an ultimate completion date of August 6, 2025. This non-set-aside, firm fixed price delivery order was competitively awarded and represents a single transaction under the company's larger contract vehicle with DLA. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,316.84 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ML 3ML insulin, with an ultimate completion date of August 8, 2025. This non-set-aside, competitively awarded contract uses firm fixed price terms and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a $1,301.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ML 3ML insulin, with an ultimate completion date of July 28, 2025. This non-set-aside contract represents a direct delivery of pharmaceutical products to support federal medical supply requirements. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for military and...
- The Defense Logistics Agency awarded a delivery order valued at $13,711.44 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ML 3ML insulin, with an ultimate completion date of August 19, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's facility in Conshohocken,...
- The Defense Logistics Agency awarded a $7,444.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar insulin (100 units/mL, 3mL formulation) with an ultimate completion date of July 28, 2025. This non-set-aside contract represents a competitive award to the Conshohocken, Pennsylvania-based pharmaceutical distributor, reflecting DLA's ongoing procurement of critical medical supplies for military and federal healthcare systems. The delivery order is issued under...
- AmerisourceBergen Drug Corp has been awarded a firm fixed-price delivery order valued at $1,278.50 by the Defense Logistics Agency (DLA) for the supply of Lantus SoloStar 100 Unit/mL insulin in 3mL quantities. The award, issued on August 8, 2025, represents a competitive procurement with no set-aside designation and is scheduled for completion by August 11, 2025. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a $2,119.98 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin medication, with a completion date of August 1, 2025. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively made with no set-aside designation, and performance will...
- The Defense Logistics Agency awarded a delivery order valued at $1,550.58 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Lantus SoloStar 100 Unit/mL insulin in 3 mL vials. This firm fixed price, non-set-aside contract is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) designated SPE2DX with the DLA Troop Support Medical, which carries a potential value of $999,999,999.00 through December 2026. The order is scheduled for completion by August...
- SPE2DB22D1200Indefinite Delivery Contract
- SPE2DB22D1200-SPE2DB25FN3YMDelivery Order
The Defense Logistics Agency has awarded a delivery order valued at $1,965.00 to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 Unit/ML insulin, with a completion date of August 21, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the pharmaceutical distributor's corporate office in Conshohocken, Pennsylvania, where the company is headquartered. The contract falls under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026 that enables the company to supply a broad range of medications and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp serves as a critical vendor within the Defense Logistics Agency's Medical Supply Chain, consistently fulfilling federal procurement requirements through competitive awards. The company's extensive portfolio includes diabetes medications, neurological treatments, pain management pharmaceuticals, antibiotics, and specialized medical supplies across multiple therapeutic domains. This particular delivery order represents a small-value transaction typical of the company's routine fulfillment operations supporting military and veteran healthcare systems through the DLA's pharmaceutical prime vendor network.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 8/20/25 |